Vanguard Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
Other funds holding MDGL
BBA
Vanguard Capital Management's MDGL Position: Q3 2026 in Review
Vanguard Capital Management increased its Madrigal Pharmaceuticals (MDGL) stake by 1.3% in Q3 2026, buying an estimated $5.8M and bringing the position to 846,641 shares worth $427M. The position accounts for 0.01% of the portfolio, ranked #732.
Vanguard Capital Management first reported a position in MDGL in Q1 2026 and has held it in 3 quarters since. The position peaked at $449M in Q2 2026. 434 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.
- Vanguard Capital Management held 846,641 shares of Madrigal Pharmaceuticals worth $427M as of Q3 2026.
- Vanguard Capital Management bought 10,973 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $5.8M.
- Madrigal Pharmaceuticals made up 0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #732 holding.
- Vanguard Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Madrigal Pharmaceuticals position peaked at $449M in Q2 2026.
- 434 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.